Related Experiment Video
Updated: Mar 9, 2026

08:46
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
17.6K
Summary
Dabrafenib shows promise in treating pediatric low-grade gliomas with the BRAF V600E mutation, offering durable responses and fewer side effects than chemotherapy. Further trials are investigating combination therapy for broader BRAF-mutant tumors.
Area of Science:
- Pediatric oncology
- Molecular oncology
- Clinical pharmacology
Background:
- Low-grade gliomas (LGG) represent the most common primary brain tumors in children.
- The BRAF V600E mutation is a key driver in a subset of pediatric LGGs.
- Targeted therapies offer a promising alternative to conventional chemotherapy with potentially improved toxicity profiles.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.9K
09:43Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
Published on: May 17, 2017
12.2K